← Eichor
Study identifier: NCT05832541 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues

Condition: Peri-implantitis  ·  Sponsor: University of Baghdad

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant. A specific dental plaque bacteria could stimulate host cells, including the junctional epithelium, to secrete a range of pro-inflammatory cytokines involved in initiating the epithelial-mesenchymal transition (EMT) process. EMT has been described as the transdifferentiation of epithelial cells into motile mesenchymal cells. Moreover, cytokines and bacterial products have been highlighted as EMT-predisposing factors. The EMT process could render epithelial cells to lose their cell-cell adhesion and cell polarity that lend these cells to lose their function as an integrated epithelial barrier. E-cadherin is a calcium-dependent cell adhesion molecule that establishes cell-cell adhesion that plays a critical role in maintaining a barrier function in the human epithelium, including gingiva. The loss of E-cadherin is one of the most common biological indicators for EMT. In contrast, vimentin is an intermediate filament expressed in mesenchymal cells and is a canonical marker for EMT, which also promotes cell motility and an invasive phenotype. It is largely reported that EMT is regulated by various transcriptional factors such as Snail Family Transcriptional Repressor SNAIL1 and SNAIL2, zinc-finger E-box-binding (ZEB)1 and ZEB2 and TWIST transcription factors that suppress epithelial marker genes, and activate genes related with the…

This description comes directly from the study's public registry record.

Talk to the study team

Talib A Alnajaty  ·  009647707905702  ·  taleb.ali1105a@codental.uobaghdad.edu.iq

Talib A Alnajaty  ·  009647707905702  ·  talib.den777@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Talib A. AlnajatyKarbala, IraqRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05832541